10 research outputs found
OCENA EFEKTIVNIH DOZ RADONA, KI TEMELJIJO NA RAZLIÄNIH MERILNIH TEHNIKAH
In my master\u27s thesis, I have focused on radon gas in 43 buildings used for different purposes (23 schools, 3 kindergartens, 16 offices and a residential house) in which preliminary measurements had shown higher concentrations of radon gas. I carried out measurements of radon and short-lived radon products whilst simultaneously employing different measurement techniques. In all 43 buildings, I measured the instantaneous concentration of radon by using scintillation cellsin 18 buildings, I additionally measured the average concentration of radon by using solid state nuclear track detectors and in 10 buildings, I measured concentration retrospectively with solid state nuclear track detectors. In four selected buildings (a school, a kindergarten, an office and a residential house), I carried out the measurements by using all of the available equipment. I monitored the daily fluctuations of concentration of radon and short-lived radon products by using continuous monitors in 14 buildings. This is how I obtained the factor of radioactive equilibrium between radon and its short-lived products. Based on the results obtained, I calculated the effective doses. As the basis for calculating the doses, I used the instantaneous and average concentrations of radon and the equilibrium factor taken from literature (0.40) or own measurements. I compared the doses and critically evaluated them.
In contrast to the previous research, I researched radon exclusively in areas with increased risk for radon. I studied the influence of the working regime on the concentration of radon in different working environments (i.e. a school, a kindergarten and an office).V svoji magistrski nalogi sem se osredotoÄila na radon v 43 zgradbah razliÄne namembnosti (23 Å”ol, 3 vrtci, 16 pisarn in stanovanjska hiÅ”a), kjer so predhodne meritve pokazale poviÅ”ane koncentracije.
Izvedla sem meritve radona in radonovih kratkoživih produktov in pri tem soÄasno uporabila razliÄne merilne tehnike. V vseh 43 zgradbah sem izmerila trenutno koncentracijo radona s scintilacijskimi celicami, v 18 zgradbah dodatno tudi povpreÄno koncentracijo z detektorji jedrskih sledi in v 10 zgradbah retrospektivno koncentracijo z detektorji jedrskih sledi. V Å”tirih izbranih zgradbah (Å”ola, vrtec, pisarna, stanovanjska hiÅ”a) sem izvedla meritve z vso razpoložljivo opremo. Dnevno spreminjanje koncentracije radona in radonovih kratkoživih produktov sem spremljala s kontinuirnimi merilniki v 14 zgradbah in tako dobila faktor radioaktivnega ravnotežja (ravnotežni faktor) med radonovimi kratkoživimi produkti in radonom. Na osnovi dobljenih rezultatov sem ocenila efektivne doze. Kot osnovo za izraÄun doz sem uporabila izmerjene trenutne in povpreÄne koncentracije radona ter ravnotežni faktor iz literature (0.40) ali meritev. Doze sem primerjala med seboj in jih kritiÄno ocenila.
Za razliko od dosedanjih raziskav, sem radon preiskovala izkljuÄno na podroÄjih s poveÄanim tveganjem. Å tudirala sem vpliv delovnega režima na koncentracijo radona v razliÄnih delovnih okoljih (Å”ola, vrtec, pisarna)
EFFECT OF TUMOR NECROSIS FACTOR ALPHA INHIBITORS ON DENDRITIC CELLS IN INTESTINAL MUCOSA OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Prebavni trakt je stalno v stiku s Å”tevilnimi antigeni, zato mora imunski sistem prepoznati in odstraniti Å”kodljive mikrobe ter hkrati razviti imunsko toleranco proti neÅ”kodljivim mikrobom. Velik pomen pri regulaciji imunskega odziva imajo dendritiÄne celice. Motnja v regulaciji imunskega odziva pri genetsko predisponirani osebi lahko vodi v razvoj kroniÄne vnetne Ärevesne bolezni.
V doktorski nalogi smo skuÅ”ali razjasniti vpliv zaviralcev tumor nekroznega faktorja alfa (TNFα) na dendritiÄne celice (DC) bolnikov s kroniÄno vnetno Ärevesno boleznijo ter opredeliti njihovo vlogo pri odzivu na tovrstno zdravljenje. Želeli smo poiskati napovedne dejavnike s pomoÄjo katerih bi lahko napovedali odziv na takÅ”no zdravljenje.
V raziskavo smo vkljuÄili trideset bolnikov s kroniÄno vnetno Ärevesno boleznijo (14 z ulceroznim kolitisom in 16 s Crohnovo boleznijo). Vsem bolnikom smo odvzeli bioptiÄne vzorce sluznice debelega Ärevesa pred zdravljenjem z zaviralci TNFα(infliksimab pri trinajstih bolnikih ter adalimumab pri sedemnajstih bolnikih) in po njem. S pretoÄno citometrijo smo v odvzetih vzorcih Ärevesne sluznice opredelili fenotip in delež konvencionalnih in plazmacitoidnih dendritiÄnih celic. Aktivnost bolezni pred zaÄetkom zdravljenja in po njem smo ocenjevali endoskopsko.
Pred zaÄetkom zdravljenja je bil delež konvencionalnih dendritiÄnih celic v vneti sluznici viÅ”ji (7,8 %) kot v nevneti (4,5 %p = 0,003), medtem ko je bil delež dendritiÄnih celic, ki so izražale CD103+, v vneti sluznici nižji (47,1 %) kot v nevneti (57,3 %p = 0,03). Po 12 tednih zdravljenja je delež konvencionalnih dendritiÄnih celic v vneti sluznici upadel s 7,8 % na 4,5 % (p = 0,014), delež dendritiÄnih celic CD103+ je ostal nespremenjen. 18 bolnikov (60 %) se je odzvalo na zdravljenje z zaviralci TNFα. V vneti sluznici teh bolnikov je bil delež konvencionalnih dendritiÄnih celic pred zdravljenjem pomembno viÅ”ji kot pri neodzivnih bolnikih (9,16 % proti 4,4 %p < 0,01). Pri teh bolnikih je bila tudi viÅ”ja izraženost HLA-DR na povrÅ”ini DC (MFI 12152 proti 8837p = 0,038).
DoloÄanje deleža konvencionalnih dendritiÄnih celic v vneti sluznici bolnikov s kroniÄno vnetno Ärevesno boleznijo pred zaÄetkom zdravljenja bi lahko uporabili kot napovednik odziva na zdravljenje z zaviralci TNFα. 93 % bolnikov z deležem konvencionalnih dendritiÄnih celic nad 7 % se je namreÄ odzvalo na zdravljenje.Inappropriate immune response to gut microbiota is involved in the pathogenesis of inflammatory bowel disease. Dendritic cells play a crucial role in the control of inflammation and immune tolerance in the gut.
We aimed to investigate the effects of tumor necrosis factor alpha (TNFα) inhibitors on intestinal dendritic cells of patients with inflammatory bowel disease and their potential role in predicting response to treatment. Also, we wished to find the predictors of response on such treatment.
Intestinal biopsies (inflamed and uninflamed areas) were obtained from 30 patients with inflammatory bowel disease (14 ulcerative colitis patients and 16 Crohn\u27s disease patients) before and after the treatment with TNFαinhibitors (infliximab 13 patients, adalimumab 17 patients). The proportions of lamina propria dendritic cells phenotypes were analyzed using flow cytometry. Disease activity was endoscopically assessed at baseline and after induction treatment.
At baseline, the proportion of conventional dendritic cells was higher in inflamed (7,8%) compared to uninflamed mucosa (4,5%) (p = 0.003) and the proportion of CD103+ dendritic cells was lower in inflamed (47,1%) versus uninflamed mucosa (57,3%) (p = 0.03). After 12 weeks of treatment, the proportion of conventional dendritic cells in inflamed mucosa decreased from 7,8% to 4,5% (p = 0.014), whereas the proportion of CD103+ dendritic cells remained unchanged. 18 out of 30 (60%) patients responded to treatment at week 12. Responders had significantly higher proportion of conventional dendritic cells (9,16% vs 4,4%, p < 0.01) with higher expression of HLA-DR (MFI 12152 vs 8837, p = 0.038) in inflamed mucosa before treatment compared to non-responders.
The proportion of conventional dendritic cells above 7% in inflamed inflammatory bowel disease mucosa before treatment predicts endoscopic response to TNFαinhibitors. 93% of patients with proportion of conventional dendritic cells above 7% responded to treatment
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
Background and Objectives: The subcutaneous (SC) formulation of vedolizumab has proven to be effective for the maintenance of remission after intravenous induction. Little is known about the efficacy of switching from intravenous maintenance treatment to SC. We aimed to assess the real-world efficacy of switching to SC treatment and to assess the impact of a baseline treatment regimen. Materials and Methods: In this observational cohort study, adult patients with inflammatory bowel disease who were switched to SC vedolizumab maintenance treatment were enrolled. Patients after intravenous induction and patients who switched from intravenous maintenance treatment (every 8 weeks or every 4 weeks) were included. The SC vedolizumab dosing was 108 mg every 2 weeks, regardless of the previous regimen. The clinical, biochemical, and endoscopic disease activity parameters and vedolizumab serum concentrations at the time of the switch and at the follow-up were assessed. Results: In total, 135 patients (38% Crohnās disease, 62% ulcerative colitis) were switched to SC vedolizumab treatment. The median time to the first follow-up (FU) was 14.5 weeks (IQR 12ā26), and the median time to the second FU was 40 weeks (IQR 36ā52). Nine patients (7%) discontinued SC vedolizumab treatment, with two-thirds of them discontinuing due to active disease. In all dosing regimens, there were no significant changes in the clinical scores and CRP at the baseline and first and second FUs. Clinical and biochemical remission appeared to be maintained irrespective of the previous dosing regimen. Conclusions: The results of this real-world study suggest that the maintenance of clinical and biomarker remission can be achieved in patients who switched from intravenous to SC vedolizumab. The baseline vedolizumab dosing regimen (every 4 weeks versus every 8 weeks) did not have an impact on outcomes
Insights into treatment of complex Crohn's perianal fistulas
Complex perianal fistula is a common complication of Crohn's disease (CD) which leads to negative impact on patient's quality of life. Successful management of the disease requires a multidisciplinary approach, including a gastroenterologist and a colorectal surgeon, applying combined surgical and medical therapy. One of frequently practiced surgical procedures is seton placement in the fistula tract, which is used to control perianal sepsis and drain the fistula, while preventing recurrent abscess formation.Darvadstrocel, a suspension of expanded, allogeneic, adipose-derived, mesenchymal stem cells, is safe and effective for treatment-refractory complex perianal fistulas in patients with Crohn's disease. Following approval of darvadstrocel, the INSPIRE registry is being conducted in order to evaluate long-term safety and effectiveness of the drug on a large, heterogenous population.An online expert meeting was held from March 20 to March 30, 2023, which provided relevant insights into the decision-making process regarding seton use and obtained feedback on the first experiences with darvadstrocel. The aim of this article is to present the perspectives from gastroenterologists and colorectal surgeons practicing in Czechia, Hungary, Israel, Lithuania, Serbia, and Slovenia in topics such as diagnosis and treatment options for patients with complex Crohn's perianal fistulas (CPF), specifically focusing on the use of setons and darvadstrocel.During this virtual session, unavailability of comprehensive data on safety and efficacy of available treatment procedures was emphasized as an important obstacle towards development of standardized recommendations and improvement of outcomes in treatment of (CPF). Furthermore, achieving consensus in seton use, duration of its placement, and frequency of change is recognized as one of CPF treatments major challenges. Despite these issues, it is important to promote better understanding and treatment of complex perianal fistulas in order to improve the quality of life of those affected by this condition
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
BACKGROUND & AIMS: Little is known about the relationship between ustekinumab exposure during the first 2 weeks of treatment and outcomes of patients with Crohn's disease (CD). We investigated the relationship between serum concentrations of ustekinumab during the first 2 weeks of treatment and endoscopic and biochemical remission in patients with CD. METHODS: In a prospective observational study, we measured concentrations of ustekinumab in serum samples from 41 consecutive patients who started treatment with ustekinumab (approximately 6 mg/kg, intravenously, then 90 mg every 8 weeks), due to endoscopic markers of active CD, at a single center from October 2017 through January 2019. We measured ustekinumab exposure parameters during the first 2 weeks (peak concentration measured immediately after intravenous infusion, week 2 concentration, and area under the curve through week 2). We investigated the correlation between these parameters and endoscopic remission (simple endoscopic score for CD scores of 3 or less without ulceration, assessed centrally) and biochemical remission (level of fecal calprotectin below 100 mg/kg) using the Mann-Whitney U test. RESULTS: Endoscopic remission was achieved in 10 patients (24.4%) at week 24; biochemical remission was achieved in 17 patients (41.5%) at week 8, 17 patients (41.5%) at week 16, and 21 patients (51.2%) at week 24. Peak concentrations associated with endoscopic remission (area under the receiver operating characteristic curve, 0.717; 95% CI, 0.517-0.916); 6 of 13 patients (46%) with peak concentrations above 105 Ī¼g/mL (upper tercile) achieved endoscopic remission, compared with only 1 of 14 patients (7%) with peak concentrations below 88 Ī¼g/mL (lower tercile). All exposure parameters during the first 2 weeks were associated with biochemical remission. There was no significant difference between the associations of peak concentrations, week-2 concentrations, area under the curve through week 2, or later exposure measures (at weeks 4 and 8) with biochemical or endoscopic remission. CONCLUSIONS: In a prospective study, we found that serum concentrations of ustekinumab as early as 1 hour after intravenous infusion might be used to identify patients with CD most likely to achieve endoscopic remission. This early measurement might be used to optimize treatment of CD.status: Published onlin
Slovenska priporoÄila za obravnavo odraslih bolnikov s kroniÄno odpovedjo prebavil
no abstractSlovenska priporoÄila za obravnavo bolnikov z kroniÄno odpovedjo prebavil so povzeta so po smernicah Evropskega združenja za kliniÄno prehrano in metabolizem (angl. ESPEN; European Society for Clinical Nutrition and Metabolism) in prilagojena slovenskim izkuÅ”njah zdravljenja odpovedi prebavil. Pretežni del bolnikov z odpovedjo prebavil predstavljajo bolniki s sindromom kratkega Ärevesa (SKÄ), zato je poudarek priporoÄil na diagnostiki, obravnavi in zdravljenju bolnikov s SKÄ. Namen priporoÄil je vzpostavitev bolj uÄinkovite prepoznave in obravnave bolnikov z odpovedjo ter vzpostavitvi temeljnih strokovnih izhodiÅ”Ä za zdravljenje teh bolnikov v Sloveniji. Dejavnost zdravljenja kroniÄne odpovedi prebavil z parenteralno prehrano na domu pri odrasli pacientih je bila v Sloveniji formalno vzpostavljena leta 2008, v 13 letih smo zdravili veÄ kot 230 pacientov, v zaÄetku leta 2021 je v 2 centrih (OI Ljubljana, UKC Ljubljana) v zdravljenje vkljuÄeno 95 odraslih bolnikov. Pred 6 leti Smo paciente v programu zdravljenja odpovedi prebavil v okviru OI LjubljanA vkljuÄili v evropski register premljanja bolnikov na Parenteralni prehrani na domu (PPD), v okviru ESPEN
Genska terapija v onkologiji, prvi razvojni koraki v Sloveniji
Gene therapy is also attracting interest in oncology. Probably the most interesting approach is immunostimulation. Plasmid DNA can be constructed, which is coding for a specific immunostimulatory molecule, which is then delivered into the cells, either in tumour or normal tissue. The transfected tissue then becomes the producer of the molecules encoded in the plasmid. The product is then released from the cells, either locally or systemically into the bloodstream. Since plasmids have hampered transport through the plasma membrane, delivery systems are needed that are either viral or nonviral. In our studies we predominantly use the non-viral transfection system, based on electroporation of the cells.Interleukin 12 (IL-12) is a cytokine with well-known anti-tumour and anti-angiogenic function. Therefore, in the SmartGene.si project we wanted to construct a plasmid DNA which is coding for IL-12 (plasmid phIL12), and perform all the necessary testing and prepare the documentation for its clinical testing in the treatment of skin tumours. The SmartGene.si consortium comprises partners from academia and industry. In the project it was necessary to prepare the plasmid according to the European Medicinal Agency (EMA) recommendations. For the application for the study approval submitted to the Agency for Medical Products and Medical Devices of the Republic of Slovenia (JAZMP), it was necessary to perform pharmacological, pharmacokinetic, and efficiency testing of phIL12. Thereafter, we had to develop the process and the facility, and prepare the drug.During the last three years, we have achieved all the goals and obtained the approval of the JAZMP for clinical testing of the product phIL12 in humans. We also obtained the approval of the National Ethics Committee. Currently, we are testing phIL-12 in a Phase I clinical protocol on head and neck skin tumours, with the aim to test the safety and feasibility of intratumoral gene electrotransfer of the plasmid phIL12. Another goal of the study is to determine a suitable dose of plasmid that could be used in future studies as adjuvant treatment to ablative therapies such as radiotherapy or electrochemotherapy.Genska terapija postaja Äedalje bolj zanimiva tudi v onkologiji. Med aplikacijami je morda najzanimivejÅ”a imunostimulacija. Pripravimo lahko plazmidno DNA, ki nosi zapis za razliÄne imunostimulatorne molekule, ki jih vnesemo v celice tumorjev ali normalnih tkiv. Ta tkiva postanejo proizvajalci teh molekul, ki lahko delujejo lokalno ali pa se izloÄajo tudi sistemsko v krvni obtok. Ker plazmidna DNA ne prehaja celiÄne membrane, so potrebni dostavni sistemi, virusni ali nevirusni. V naÅ”ih Å”tudijah uporabljamo predvsem nevirusni dostavni sistem ā elektroporacijo.Interlevkin 12 (IL-12) je eden od zanimivih citokinov, za katerega je znano protitumorsko delovanje s spodbujanjem imunskega odziva in antiangiogenim delovanjem. Namen projekta SmartGene.si je bil pripraviti plazmid z zapisom za interlevkin 12 (plazmid phIL12) in pripraviti vse potrebno za njegovo kliniÄno testiranje za zdravljenje kožnih tumorjev. V konzorciju smo združili moÄi s partnerji z akademskega in industrijskega podroÄja. Treba je bilo pripraviti plazmid za uporabo v humani onkologiji po zahtevah Evropske agencije za zdravila (EMA). Za prijavo kliniÄne Å”tudije na Javno agencijo za zdravila in medicinske pripomoÄke (JAZMP) smo morali izvesti tudi vse nekliniÄne raziskave o varnosti in uÄinkovitosti zdravila. Nato je bilo treba razviti postopek priprave zdravila, zagotoviti primerne prostore za pripravo in izvedbo postopka priprave zdravila.V treh letih smo dosegli vse te zastavljene cilje in dobili dovoljenje za izvajanje kliniÄne Å”tudije na kožnih tumorjih, ki ga je izdala JAZMP na osnovi pozitivnega mnenja Komisije Republike Slovenije za medicinsko etiko. Zdaj poteka kliniÄna Å”tudija faze I preizkuÅ”anja plazmida phIL12 na kožnih tumorjih glave in vratu z namenom preveriti varnost in sprejemljivost genskega elektroprenosa plazmida v tumorje. Cilj Å”tudije je prav tako doloÄiti primeren odmerek zdravila, ki bi ga v nadaljnji kliniÄni Å”tudiji uporabili kot adjuvantno zdravljenje k ablativnim terapijam, kot sta radioterapija ali elektrokemoterapija
Gene therapy in oncology, first steps of development in Slovenia
Genska terapija postaja Äedalje bolj zanimiva tudi v onkologiji. Med aplikacijami je morda najzanimivejÅ”a imunostimulacija. Pripravimo lahko plazmidno DNA, ki nosi zapis za razliÄne imunostimulatorne molekule, ki jih vnesemo v celice tumorjev ali normalnih tkiv. Ta tkiva postanejo proizvajalci teh molekul, ki lahko delujejo lokalno ali pa se izloÄajo tudi sistemsko v krvni obtok. Ker plazmidna DNA ne prehaja celiÄne membrane, so potrebni dostavni sistemi, virusni ali nevirusni. V naÅ”ih Å”tudijah uporabljamo predvsem nevirusni dostavni sistem ā elektroporacijo. Interlevkin 12 (IL-12) je eden od zanimivih citokinov, za katerega je znano protitumorsko delovanje s spodbujanjem imunskega odziva in antiangiogenim delovanjem. Namen projekta SmartGene.si je bil pripraviti plazmid z zapisom za interlevkin 12 (plazmid phIL12) in pripraviti vse potrebno za njegovo kliniÄno testiranje za zdravljenje kožnih tumorjev. V konzorciju smo združili moÄi s partnerji z akademskega in industrijskega podroÄja. Treba je bilo pripraviti plazmid za uporabo v humani onkologiji po zahtevah Evropske agencije za zdravila (EMA). Za prijavo kliniÄne Å”tudije na Javno agencijo za zdravila in medicinske pripomoÄke (JAZMP) smo morali izvesti tudi vse nekliniÄne raziskave o varnosti in uÄinkovitosti zdravila. Nato je bilo treba razviti postopek priprave zdravila, zagotoviti primerne prostore za pripravo in izvedbo postopka priprave zdravila. V treh letih smo dosegli vse te zastavljene cilje in dobili dovoljenje za izvajanje kliniÄne Å”tudije na kožnih tumorjih, ki ga je izdala JAZMP na osnovi pozitivnega mnenja Komisije Republike Slovenije za medicinsko etiko. Zdaj poteka kliniÄna Å”tudija faze I preizkuÅ”anja plazmida phIL12 na kožnih tumorjih glave in vratu z namenom preveriti varnost in sprejemljivost genskega elektroprenosa plazmida v tumorje. Cilj Å”tudije je prav tako doloÄiti primeren odmerek zdravila, ki bi ga v nadaljnji kliniÄni Å”tudiji uporabili kot adjuvantno zdravljenje k ablativnim terapijam, kot sta radioterapija ali elektrokemoterapija.Gene therapy is also attracting interest in oncology. Probably the most interesting approach is immunostimulation. Plasmid DNA can be constructed, which is coding for a specific immunostimulatory molecule, which is then delivered into the cells, either in tumour or normal tissue. The transfected tissue then becomes the producer of the molecules encoded in the plasmid. The product is then released from the cells, either locally or systemically into the bloodstream. Since plasmids have hampered transport through the plasma membrane, delivery systems are needed that are either viral or nonviral. In our studies we predominantly use the non-viral transfection system, based on electroporation of the cells. Interleukin 12 (IL-12) is a cytokine with well-known anti-tumour and anti-angiogenic function. Therefore, in the SmartGene.si project we wanted to construct a plasmid DNA which is coding for IL-12 (plasmid phIL12), and perform all the necessary testing and prepare the documentation for its clinical testing in the treatment of skin tumours. The SmartGene.si consortium comprises partners from academia and industry. In the project it was necessary to prepare the plasmid according to the European Medicinal Agency (EMA) recommendations. For the application for the study approval submitted to the Agency for Medical Products and Medical Devices of the Republic of Slovenia (JAZMP), it was necessary to perform pharmacological, pharmacokinetic, and efficiency testing of phIL12. Thereafter, we had to develop the process and the facility, and prepare the drug. During the last three years, we have achieved all the goals and obtained the approval of the JAZMP for clinical testing of the product phIL12 in humans. We also obtained the approval of the National Ethics Committee. Currently, we are testing phIL-12 in a Phase I clinical protocol on head and neck skin tumours, with the aim to test the safety and feasibility of intratumoral gene electrotransfer of the plasmid phIL12. Another goal of the study is to determine a suitable dose of plasmid that could be used in future studies as adjuvant treatment to ablative therapies such as radiotherapy or electrochemotherapy
6th International Conference The Future of Information Sciences INFuture2017: Integrating ICT in Society
This is the sixth publication in the series of biennial international conferences, The Future of Information Sciences (INFuture) organised by the Department of Information and Communication Sciences, Faculty of Humanities and Social Sciences, University of Zagreb. This year it is co-organised with the Miroslav Krleža Institute of Lexicography. The title of the conference is INFuture2017: Integrating ICT in Society. The conference explores the influence the information and communication sciences have on the society as a whole.This is the sixth publication in the series of biennial international conferences, The Future of Information Sciences (INFuture) organised by the Department of Information and Communication Sciences, Faculty of Humanities and Social Sciences, University of Zagreb. This year it is co-organised with the Miroslav Krleža Institute of Lexicography. The title of the conference is INFuture2017: Integrating ICT in Society. The conference explores the influence the information and communication sciences have on the society as a whole
6th International Conference The Future of Information Sciences INFuture2017: Integrating ICT in Society
This is the sixth publication in the series of biennial international conferences, The Future of Information Sciences (INFuture) organised by the Department of Information and Communication Sciences, Faculty of Humanities and Social Sciences, University of Zagreb. This year it is co-organised with the Miroslav Krleža Institute of Lexicography. The title of the conference is INFuture2017: Integrating ICT in Society. The conference explores the influence the information and communication sciences have on the society as a whole.This is the sixth publication in the series of biennial international conferences, The Future of Information Sciences (INFuture) organised by the Department of Information and Communication Sciences, Faculty of Humanities and Social Sciences, University of Zagreb. This year it is co-organised with the Miroslav Krleža Institute of Lexicography. The title of the conference is INFuture2017: Integrating ICT in Society. The conference explores the influence the information and communication sciences have on the society as a whole